FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124731595> ?p ?o ?g. }

• W2124731595 endingPage "567" @default.
• W2124731595 startingPage "561" @default.
• W2124731595 abstract "Temsirolimus showed clinical efficacy in refractory squamous cell carcinoma of the head and neck (SCCHN), who failed platinum and epidermal growth factor receptor inhibition. Tumor shrinkage in 39% and a progression-free survival rate of 40% at 12 weeks warrants future studies in SCCHN, which may define a novel treatment paradigm in SCCHN. However, no predictive molecular marker was identified.BackgroundSquamous cell carcinoma of the head and neck (SCCHN) is a common disease, which has a poor prognosis after failure of therapy. Activation of the PI3K–AKT–mTOR axis is commonly detected in recurrent or metastatic SCCHN, and provided the rationale for the clinical phase II trial in pretreated SCCHN.Patients and methodsThe primary end point was the progression-free survival rate (PFR) at 12 weeks. Forty eligible patients have been recruited after failure of platinum chemotherapy and cetuximab. A preplanned futility analysis was successfully passed after ≥1 success was detected in 20 patients. Secondary objectives consisted of progression-free survival (PFS), disease control rate (DCR), overall survival (OS), safety and tolerability, and predictive biomarkers for KRAS, BRAF, PIK3CA mutations, and HPV status. Archived tumor tissue was analyzed for DNA sequence.ResultsA total of 40 patients were eligible. The PFR at 12 weeks was 40% (95% CI 25.0–54.6). The median PFS and OS were 56 days (95% CI 36–113 days) and 152 days (76–256 days), respectively. In 33 assessable patients, disease stabilization occurred in 57.6%, with tumor shrinkage in 13 patients (39.4%). Overall, the treatment was well tolerated. Fatigue (47.5%), anemia (25.0%), nausea (20.0%), and pneumonia (20.0%) were the most common adverse events. Neither PIK3CA mutations, nor HPV status were predictive for success with temsirolimus treatment. No mutations were found for KRAS or BRAF.ConclusionTumor shrinkage and efficacy parameter indicate that inhibition of the PI3K–AKT–mTOR axis was a putative novel treatment paradigm for SCCHN. We could not identify parameters predictive for treatment success of temsirolimus, which underscores the need for refinement of the molecular analysis in future studies.Clinical trials numberNCT01172769." @default.
• W2124731595 created "2016-06-24" @default.
• W2124731595 creator A5001987856 @default.
• W2124731595 creator A5026803534 @default.
• W2124731595 creator A5029385951 @default.
• W2124731595 creator A5033494849 @default.
• W2124731595 creator A5047006205 @default.
• W2124731595 creator A5049496369 @default.
• W2124731595 creator A5054422040 @default.
• W2124731595 creator A5066131806 @default.
• W2124731595 creator A5066640097 @default.
• W2124731595 creator A5069058671 @default.
• W2124731595 creator A5074854571 @default.
• W2124731595 creator A5074991092 @default.
• W2124731595 creator A5077225173 @default.
• W2124731595 date "2015-03-01" @default.
• W2124731595 modified "2023-10-09" @default.
• W2124731595 title "TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)" @default.
• W2124731595 cites W1535004310 @default.
• W2124731595 cites W1972963227 @default.
• W2124731595 cites W1978301900 @default.
• W2124731595 cites W1997552014 @default.
• W2124731595 cites W2005777961 @default.
• W2124731595 cites W2026569756 @default.
• W2124731595 cites W2055827129 @default.
• W2124731595 cites W2071588497 @default.
• W2124731595 cites W2072120847 @default.
• W2124731595 cites W2091973648 @default.
• W2124731595 cites W2102648794 @default.
• W2124731595 cites W2103799963 @default.
• W2124731595 cites W2110664940 @default.
• W2124731595 cites W2112845420 @default.
• W2124731595 cites W2122357705 @default.
• W2124731595 cites W2136693809 @default.
• W2124731595 cites W2136871952 @default.
• W2124731595 cites W2138010881 @default.
• W2124731595 cites W2139248078 @default.
• W2124731595 cites W2140747142 @default.
• W2124731595 cites W2141983633 @default.
• W2124731595 cites W2148424438 @default.
• W2124731595 cites W2157400190 @default.
• W2124731595 cites W2159791307 @default.
• W2124731595 cites W3004116704 @default.
• W2124731595 doi "https://doi.org/10.1093/annonc/mdu571" @default.
• W2124731595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25527417" @default.
• W2124731595 hasPublicationYear "2015" @default.
• W2124731595 type Work @default.
• W2124731595 sameAs 2124731595 @default.
• W2124731595 citedByCount "55" @default.
• W2124731595 countsByYear W21247315952015 @default.
• W2124731595 countsByYear W21247315952016 @default.
• W2124731595 countsByYear W21247315952017 @default.
• W2124731595 countsByYear W21247315952018 @default.
• W2124731595 countsByYear W21247315952019 @default.
• W2124731595 countsByYear W21247315952020 @default.
• W2124731595 countsByYear W21247315952021 @default.
• W2124731595 countsByYear W21247315952022 @default.
• W2124731595 countsByYear W21247315952023 @default.
• W2124731595 crossrefType "journal-article" @default.
• W2124731595 hasAuthorship W2124731595A5001987856 @default.
• W2124731595 hasAuthorship W2124731595A5026803534 @default.
• W2124731595 hasAuthorship W2124731595A5029385951 @default.
• W2124731595 hasAuthorship W2124731595A5033494849 @default.
• W2124731595 hasAuthorship W2124731595A5047006205 @default.
• W2124731595 hasAuthorship W2124731595A5049496369 @default.
• W2124731595 hasAuthorship W2124731595A5054422040 @default.
• W2124731595 hasAuthorship W2124731595A5066131806 @default.
• W2124731595 hasAuthorship W2124731595A5066640097 @default.
• W2124731595 hasAuthorship W2124731595A5069058671 @default.
• W2124731595 hasAuthorship W2124731595A5074854571 @default.
• W2124731595 hasAuthorship W2124731595A5074991092 @default.
• W2124731595 hasAuthorship W2124731595A5077225173 @default.
• W2124731595 hasBestOaLocation W21247315951 @default.
• W2124731595 hasConcept C121608353 @default.
• W2124731595 hasConcept C126322002 @default.
• W2124731595 hasConcept C143998085 @default.
• W2124731595 hasConcept C183713625 @default.
• W2124731595 hasConcept C185592680 @default.
• W2124731595 hasConcept C190283241 @default.
• W2124731595 hasConcept C2776530083 @default.
• W2124731595 hasConcept C2776694085 @default.
• W2124731595 hasConcept C2776820818 @default.
• W2124731595 hasConcept C2777472916 @default.
• W2124731595 hasConcept C2779998722 @default.
• W2124731595 hasConcept C2780739268 @default.
• W2124731595 hasConcept C2781187634 @default.
• W2124731595 hasConcept C31760486 @default.
• W2124731595 hasConcept C526805850 @default.
• W2124731595 hasConcept C55493867 @default.
• W2124731595 hasConcept C71924100 @default.
• W2124731595 hasConcept C86554907 @default.
• W2124731595 hasConceptScore W2124731595C121608353 @default.
• W2124731595 hasConceptScore W2124731595C126322002 @default.
• W2124731595 hasConceptScore W2124731595C143998085 @default.
• W2124731595 hasConceptScore W2124731595C183713625 @default.
• W2124731595 hasConceptScore W2124731595C185592680 @default.
• W2124731595 hasConceptScore W2124731595C190283241 @default.
• W2124731595 hasConceptScore W2124731595C2776530083 @default.

• next